Vasculitis Foundation
PO Box 28660
Kansas City MO 64188-8660
Web and Phone Contact
Telephone (816) 436-8211
Fax 816- 656-3838
Mission Statement

Building upon the collective strength of the vasculitis community, the Foundation supports, inspires and empowers individuals with vasculitis and their families through a wide range of education, research, clinical, and awareness initiatives.

(ratified 12.13.2017)

CEO/Executive Director Ms. Joyce A Kullman
Board Chair Suzanne DePaolis
Board Chair Company Affiliation Community volunteer
History and Background
Year of Incorporation 1986
Former Names
Wegener's Granulomatosis Association
Wegener's Granulomatosis Support Group, International
Volunteer Opportunities
Ways to donate, support, or volunteer We are pleased to accept donations via our website, phone, or mail. We also accept in-kind donations, matching employee corporate gifts and volunteers.  We also accept gifts in honor and in memory of our patients and members. 
Financial Summary
Revenue Expense Area Graph

Comparing revenue to expenses shows how the organizations finances fluctuate over time.

Source: IRS Form 990

Net Gain/Loss:    in 
Note: When component data are not available, the graph displays the total Revenue and/or Expense values.
Mission Statement

Building upon the collective strength of the vasculitis community, the Foundation supports, inspires and empowers individuals with vasculitis and their families through a wide range of education, research, clinical, and awareness initiatives.

(ratified 12.13.2017)

Background Statement
The VF (formerly the Wegener's Granulomatosis Association) was founded in 1986 by Marilyn Sampson, RN, a patient with Wegener's Granulomatosis. When Marilyn was diagnosed in 1978, the prognosis for Wegener's patients was six months to two years. She died in 1997 from cancer unrelated to her Wegener's.
As a registered nurse, Marilyn was frustrated by the lack of information for patients. She wrote the first patient information packet and networked with doctors around the world to find other Wegener's patients. In 1987 she published the first newsletter and in 1994 organized the first patient symposium. In 1995 the group launched its first website and membership grew by 100s almost overnight.
Over the past 30+ years, the Vasculitis Foundation (name change in 2006) has provided detailed educational materials on all the forms of vasculitis for patients, family members, medical professionals, and the general public.  The bimonthly 16-page newsletter includes updates on advances made in treatment and research as well as VF activities.  The website receives over 9,000 visitors a month and is recognized as an excellent resource on vasculitis.
The VF also has a network of international area contacts and chapters across the U.S., Australia, Canada, Denmark, France, Germany, Ireland, Italy, Mexico, New Zealand, Sweden, and the United Kingdom.  The VF hosts a biennial international patient symposium, which brings together patients, families, and vasculitis experts to learn about advances in treatment and research. The meeting also provides an opportunity for attendees to meet and share experiences.
In 2001 the VF established its Small Grant Research Program (now the Research Program) and to date has funded over $2 million in research on the cause and treatment of vasculitis.  The Research Program funds novel studies seeking the cause(s) of vasculitis, more effective treatments and a cure for vasculitis.  The VF Medical Consultants and Scientific Advisory Board are among the world's finest and most experienced doctors who care for patients and conduct research; they also provide free consultation to physicians treating patients with vasculitis as their schedules permit.
Impact Statement
The Vasculitis Foundation is the largest private funder of research on vasculitis and collaborates with researchers around the world to fund novel and innovative pilot studies.  In March 2016 we broke the $2 million mark in funding research since the program was established in 2002.  We currently have 13 research studies and one fellowship underway at the National Institutes of Health and Georgetown University Hospital.  In 2019 we funded our 50th research study.     
In 2016 we have partnered with the Northwestern University Medical Center to successfully establish the Vasculitis Clinical Program in the Division of Rheumatology.  Dr. Amy Archer is the director of the clinic, the first vasculitis center in the state of Illinois.
The Vasculitis Foundation provides educational materials to patients, their families, and health care professionals via its website, bimonthly newsletters, E-Newsletters, webinars, regional conferences, and international symposia. The organization's new website, launched in March 2019, receives over 9,000 unique visitors per month from around the world. 
Needs Statement
We will need to implement the General Data Protection Regulation (GDRP) Our five most pressing needs are:
  • VF Research Program:  to establish an endowment fund to enable the organization to increase the # and amount of research grants the organization can fund annually:  $5,000,000.
  • Medical Community Education:  to create continuing medical education (CME) courses to increase awareness of vasculitis in the medical community to improve diagnostic times and understanding of best treatments for vasculitis ($100,000)
  • VF Fellowship Program:  to train young physicians in the field of vasculitis ($250,000 for 5 fellows over 5 years) 
  • VF Awareness Social Media Campaign:  to create electronic and print materials for ongoing awareness and educational activities to reach our diverse patient community: $25,000
  • VF Website:  to continue expanding the VF's new website, launched in 2019 and to implement the General Data Protection Regulation. $30,000   
Service Categories
Specifically Named Diseases
Specifically Named Diseases Research
Diseases of Specific Organs
Areas of Service
Geographic Area Served Narrative The VF is the international advocacy organization for people with vasculitis. Through our website, we connect with patients, families, clinicians, and researchers around the world.  
CEO/Executive Director/Board Chair Statement
I celebrate our successes and recognize our challenges in supporting those with vasculitis through education, awareness, and research.
Increasing understanding of vasculitis, sharing best practices in disease management, and preventing complications through education will lead to improved quality of life for all of our patients around the world.  We continue to improve our educational outreach to meet the needs of all afflicted by vasculitis.  In addition to our hallmark biannual International symposia, we have expanded our educational outreach to include one-day regional educational events and technological resources webinar offerings.
The Foundation's research program funds up to four $50,000 research grants yearly.  During the 2nd Research Consensus Conference in April 2012 goals were established for future research and to establish a fellowship program.  Providing funding for training of vasculitis fellows will further the depth and breadth of care by increasing the number of vasculitis specialists both in the US and abroad.  Since adding this program, the Vasculitis Foundation has funded one VF Fellow in collaboration with the UNC Kidney Center, and one VF Fellow at the University of Pennsylvania.  We have also funded a one-year fellowship at the Cleveland Clinic.  Through our VCRC-VF Fellowship Program, we have funded one-year fellowships at the University of Toronto, McMaster's University, National Institutes of Health, and the Cleveland Clinic.      
I believe improved awareness of vasculitis in the healthcare and public community will support earlier diagnosis and disease management resulting in better patient outcomes.  We strive to improve our outreach through collaboration with other advocates including the NIH, AARDA, NORD, the V-PPRN, and the VCRC.  These efforts support awareness and assist in securing government funding towards the ongoing research and care of those with rare diseases, including many of the vasculitic disease categories.
I believe this is a great opportunity for me to give back to the organization, to share my personal and professional knowledge and experience, and to make a difference to those touched by vasculitis.
Description Knowledge is key to a patient understanding vasculitis. Through our website, bimonthly newsletter, information packets, 800 number and symposia the VF educates its members about the diseases. The educational materials provide the most current information on medications and medical procedures.
Category Health Care, General/Other Patient Education
Population Served Adults
Short-Term Success 1,500 patients worldwide will receive early diagnosis and effective treatment; 3,000 patients already diagnosed will regain their health and will be able to return to pre-disease family and work responsibilities; 2,000 will seek treatment at one of the primary vasculitis centers, and 650 of those patients will participate in research.
Long-Term Success

Patient care studies confirm that knowledge is critical in patient care. With VF support and education, 80% of patients will achieve remission sooner with fewer ongoing health challenges; 100% of patients will receive effective treatment and will "life with" vasculitis as they live life. 

Program Success Monitored By The VF asks for feedback of its Support and Education Program in the newsletter, website and information packets. The VF also issues member surveys, and provides an evaluation tool at the end of every educational conference and symposium. 
Examples of Program Success Fewer patients are suffering full flares because they know how to recognize/treat them. More patients are seeking care at the major vasculitis centers (one of our most popular suggestions). More patients are participating in research trials. Researchers are seeking out the VF's assistance in recruiting patients to their studies.
Description Vasculitis Foundation (VF) members are encouraged to raise awareness of vasculitis and the VF year-round in their local communities. Members distribute information to medical offices, hospitals, health centers, pharmacies and libraries. Vasculitis Awareness Week is celebrated in May and activities include participation at health fairs, town square events, walk/runs, dinners, golf tournaments and road rallies. Events are organized by individuals, families and VF chapters.
Category Health Care, General/Other Early Intervention & Prevention
Population Served Adults
Short-Term Success Success is defined by the number of patients who receive an early diagnosis (1-3 months from illness onset). Recently, the Vasculitis Foundation funded a two-year Epidemiology Study that helps track the number of vasculitis patients, diagnosis, etc. These statistics are vital for the Foundation, as well as the medical community. 
Long-Term Success
Research studies report that the earlier a patient is diagnosed, the more likely he/she is to recover his/her health and avoid permanent damage to vital organs and less likely to suffer from chronic health challenges. The goal of the Awareness Program is to make 100% of the medical community aware of vasculitis and to provide them with the knowledge to diagnose and effectively treat the disease. The medical community will also recognize that vasculitis is a critical health issue and demands immediate treatment.
Program Success Monitored By Members report all their awareness efforts to the VF on an ongoing basis. They report to the VF on the number of new patients and family members who contact them because of the activity. The VF also tracks new members and always asks how they learned of the VF.
Examples of Program Success
Over 10,000 people will be reached through awareness activities. Approximately 20% will join the VF where they are empowered through knowledge and support and are committed to fulfilling the VF's mission to improve lives.
The term "vasculitis" is understood by the general public.
Physicians are increasingly recognizing and able to diagnose and effectively treat vasculitis patients.
The VF Research Program was established in 2001 to encourage and support research into the cause(s), cure and treatment of vasculitis. In 2019, the VF funded its 50th study.
Category Medical Research, General/Other Medical Specialties Research
Population Served General/Unspecified
Short-Term Success

Data gathered from VF-funded research studies will be published in 45 medical journals and presented at 15 international medical conferences.

Long-Term Success
  • Increase grant awards to $300,000 per year.
  • Increase the number of VF-funded research studies to six per year.
  • Increase the collaboration between international researchers to foster new and innovative clinical and laboratory studies.
Program Success Monitored By
  1. The number of quality applications received and approved for funding.
  2. Researchers are required to submit 6 and 12 month reports as well as a final report on their projects. Funding is not released until reports are received and reviewed by the Research Committee.
  3. The number of VF-funded research projects presented at international medical meetings each year.
  4. Researchers are also encouraged to provide posters about their studies for VF meetings and symposia.
  5. The VF requests ongoing feedback from members of the Scientific Review Board.
Examples of Program Success
In 2003, the VF awarded a researcher at the Oklahoma Medical Research Foundation a research grant of $35,000. Two years later, with the results determined by our grant, the researcher applied to the National Institutes of Health and received a $1.2 million grant for further study.
To date the program has funded over $2,000,000 for research. The program underwent a complete review in 2015 and based on the results, a new application form was developed, award amounts were raised to $50,000/year or $100,000/two years and the Scientific Advisory Board was expanded to include other medical specialties. These changes will help the VF fund the most worthy research on vasculitis.

The Vasculitis Foundation Fellowship Program provides the opportunity for one- or two-year tracks designed to support the training for physician-scientists who wish to gain clinical expertise in vasculitis and who may also wish to pursue an investigational career in this field. We have funded fellowships at the University of North Carolina, Cleveland Clinic, and the University of Pennsylvania since 2013.  

In a separate initiative, the Vasculitis Foundation partners with the Vasculitis Clinical Research Consortium (VCRC) to fund one- or two-year fellowships at our VCRC centers.  We have funded fellowships at the University of Toronto, McMaster's University, the Cleveland Clinic, Mayo Clinic, and the National Institutes of Health. The Vasculitis Foundation has an annual commitment of $50,000 to support the five-year program.  
The Vasculitis Foundation recognizes the tremendous need to recruit and support the training of young physician-scientists to the field of vasculitis.    
Program Budget $250,000.00
Category Diseases, Disorders & Medical Disciplines, General/Other Diseases, Disorders & Medical Disciplines, General/Other
Population Served People/Families of People with Health Conditions
Short-Term Success
These fellows have completed their fellowships and returned to their medical institutes to establish, or assist in expanding existing vasculitis centers:
Elizabeth Bryant, MD, Dartmouth University
Rennie Rhee, University of Pennsylvania
Medha Soowamber, MD, University of Toronto
Jennifer Rodrigues, MD, McMaster's University
Hiro Tamaki, MD, Tokyo, Japan
Kaitlin Quinn, National Institutes of Health (began her second year in July 2018)
Kevin Byram, Vanderbilt University
Long-Term Success
Vasculitis is a rare disease and for many doctors, they will never treat a patient with vasculitis. Unfortunately, this means that when patients show symptoms of vasculitis, they often go unrecognized or misdiagnosed. Many areas of the United States have no experts in this field.
The VF and the VCRC-VF Fellowship Programs encourage medical students to specialize in vasculitis.  By conducting fellowships at existing Vasculitis Centers, fellows learn from world experts, and then take what they learn back to their home institutions to treat patients and conduct research on the cause and/or cure for vasculitis.
The VF has entered into a new partnership agreement with the VCRC to fund five new one-year fellowships beginning in July 2019, a financial commitment of $50,000 per year for a total of $250,000.  

The following fellows have completed their fellowships:
Elizabeth Bryant, MD, Dartmouth University
Rennie Rhee, University of Pennsylvania
Medha Soowamber, MD, University of Toronto
Jennifer Rodrigues, MD, McMaster's University
Hiro Tamaki, MD, Tokyo, Japan
Kaitlin Quinn, National Institutes of Health/Georgetown Health Care (began her second year in July 2018)
Kevin Byram, Vanderbilt University
Program Success Monitored By
The VF Fellowship Program and the VCRC-VF Fellowship Program are monitored by the VF Research Committee. 
Fellowship awardees present progress reports on their work at semi-annual meetings of the VCRC-VF and are expected to present abstracts to the American College of Rheumatology or/and other appropriate specialty meetings.  A two-page progress report must be submitted by the fellow semi-annually to the VCRC Steering Committee and the VF Research Committee.  They participate in VF international and regional symposiums and become familiar with the VF and its purpose.  The VCRC-VF Fellowship mentor also submits a one-page evaluation of the Fellow to the VCRC Steering Committee and the VF Research Committee semi-annually. 
Examples of Program Success
These fellows have completed their fellowships and returned to their medical institutes to establish or help expand existing vasculitis centers:
Elizabeth Bryant, MD, Dartmouth University
Rennie Rhee, University of Pennsylvania
Medha Soowamber, MD, University of Toronto
Jennifer Rodrigues, MD, McMaster's University
Hiro Tamaki, MD, Tokyo, Japan
Kaitlin Quinn, National Institutes of Health/Georgetown Health Care (began her second year in July 2018)
Kevin Byram, Vanderbilt University

We are a team of patients with vasculitis, caregivers, researchers, data specialists, and providers on a daily mission to share and learn from one another with a vision for the future in clinical vasculitis research.  The V-PPRN seeks to transform how clinical research in vasculitis is conducted by directly engaging patients, investigators, care providers, and health systems to develop research methods to electronically collect health records and patient-reported data on a large number of patients with various forms of vasculitis.  The goal of the V-PPRN research program is to conduct high-quality studies that will improve the care and the health of patients with vasculitis by exploring research questions that matter most to patients and advance medical knowledge about vasculitis.


Category Diseases, Disorders & Medical Disciplines, General/Other Diseases, Disorders & Medical Disciplines, General/Other
Population Served US& International
Short-Term Success The V-PPRN launched in November 2014 and to date has registered over 3,000 patients in the network.  Our original goal was 500 patients.   We have completed four research studies and launched the Vasculitis Pregnancy Registry (V-PREG), which is a long-term study enrolling women who have vasculitis who are also pregnant. There is very limited information available on how vasculitis affects pregnancy and this is an area of great concern for our patients and their families.
Long-Term Success

Over the next 5-10 years the V-PPRN will:

  • Drive new vasculitis clinical research studies
  • Engage patients in new ways
  • Directly involve patients in the design and selection of research topics
  • Significantly increase the number of patients eligible to participate
  •  Enroll a geographically diverse patient population
  • Broaden the disease spectrum by enrolling patients with many different types of vasculitis
Program Success Monitored By V-PREG is governed by a steering committee, operations committee, three working groups and an advisory council composed of patients, researchers, VF staff and support staff from the University of Pennsylvania and University of Southern Florida.  Each group conducts evaluations and the steering committee oversees the entire network.    
Examples of Program Success We have successfully completed four research studies. The studies were successful in recruiting the required # of patients and data is being compiled.   
CEO Comments The VF's programs are instrumental to the organization fulfilling its mission. Awareness leads to more patients being diagnosed, education helps patients be better patients, research improves treatments and support means that no one is battling this disease alone.
Executive Director/CEO
Executive Director Ms. Joyce A Kullman
Term Start Sept 2001
Joyce Kullman has served as executive director since February 2002. Prior to that she served on the VF Board of Directors for five years and was an active member of the Kansas City VF Chapter. 
As executive director, she has worked to:
  • Increase outreach and support services to patients and families worldwide.
  • Develop educational materials for patients, families and medical professionals to create better understanding of vasculitis.
  • Encourage medical professionals to focus on vasculitis research to increase the number of research studies and expand the areas of research.
  • Expand the VF Medical Consultants to include more geographical areas and vasculitis centers.
  • Establish the Scientific Advisory Board to assist with the VF Research Program.
  • Organize biennial symposia for patients, families and medical professionals.
Former CEOs
Ms. Iva N. RoeOct 1997 - Mar 2002
Mrs. Marilyn SampsonJan 1986 - Oct 1997
Senior Staff
Title Financial Coordinator
Experience/Biography Jennifer joined the organization in 2006 and handles the accounting and financial duties. She is a graduate of Park University and holds a Bachelor of Arts degree in Accounting and Business Administration/Marketing. She is married and the mother of one daughter.
Title Director of Marketing and Communications
Experience/Biography Ed is the founder and director of the PAN Support Network, an online advocacy group for people with Polyarteritis nodosa, a form of vasculitis.

Ed has worked extensively with the Vasculitis Foundation for over 14 years to further both organizations’ missions to help educate patients about PAN and all the vasculitides. He served on the Education and Awareness Council and joined the VF Board of Directors in 2010. In 2009, Ed and his friend (now wife), Mary Seubert, organized “The VF Power Pedal for Rare Diseases”, a week-long bike ride from Pittsburgh, Pennsylvania to Washington, D.C. 

Ed created the Extraordinary Patient Stories Video project, which now has over 100+ interviews with patients and their family members, discussing the impact that vasculitis has on their lives. 

In 2016, he helped create the Victory over Vasculitis Awareness Campaign, partnering with Brandon Hudgins, a professional long-distance runner, who also has vasculitis.  Brandon continues to champion and encourage patients to fight vasculitis with a positive attitude.  
Title Director of Research Affairs, V-PPRN Network Manager
Kalen Young has served as the V-PPRN Network Manager since April 2014. She received her Master’s in Social Justice and Human Rights in 2012 and specializes in qualitative research methodologies. Kalen has employed her professional knowledge to help develop Network-wide policies and procedures and has maintained direct oversight of all day-to-day project activities. Her experience in conducting qualitative interviews has proven helpful when implementing direct patient outreach for data compliance and engagement strategies.
Paid Full-Time Staff 5
Paid Part-Time Staff 1
Paid Contractors 2
Volunteers 150
Retention Rate 100%
Staff Diversity (Ethnicity)
African American/Black 0
Asian American/Pacific Islander 0
Caucasian 6
Staff Diversity (Gender)
Female 5
Male 1
Formal Evaluations
CEO Formal Evaluation Yes
CEO/Executive Formal Evaluation Frequency Annually
Senior Management Formal Evaluation Yes
Senior Management Formal Evaluation Frequency Annually
Non-Management Formal Evaluation Yes
Non-Management Formal Evaluation Frequency Annually
Plans & Policies
Organization Has a Fundraising Plan No
Organization Has a Strategic Plan Yes
Management Succession Plan No
Organization Policy and Procedures No
Nondiscrimination Policy Yes
Whistleblower Policy No
Document Destruction Policy Yes
  • American Autoimmune Related Diseases Association (AARDA)
  • Coalition of Patient Advocacy Groups (CPAG)
  • National Coalition of Autoimmune Patient Advocacy Groups (NCPAG)
  • Vasculitis Clinical Research Consortium (VCRC)
  • National Organization of Rare Diseases (NORD)
National Organization for Rare Disorders - Member2000
National Organization for Rare Disorders - Member2007
National Organization for Rare Disorders - Member2008
National Organization for Rare Disorders - Member2009
National Organization for Rare Disorders - Member2010
National Organization for Rare Disorders - Member2012
National Organization for Rare Disorders - Member2013
National Organization for Rare Disorders - Member2014
National Organization for Rare Disorders - Member2015
National Organization for Rare Disorders - Member2016
National Organization for Rare Disorders - Member2017
National Organization for Rare Disorders - Member2018
National Organization for Rare Disorders - Member2019
Government Licenses
Is your organization licensed by the government? No
Board Chair
Board Chair Suzanne DePaolis
Company Affiliation Community volunteer
Term Oct 2018 to Oct 2021
Board Members
Ms. Sara Baird Amodio
Ms. Suzanne DePaolis
Ms. Jacquelyn Eidson
Dr. Peter Grayson MD
Ms. Karen HirschCommunity Volunteer
Mr. Victor James
Ms. Allison Lint Ross
Mr. Don Nagle
Ms. Pamela Pekerman
Dr. Jason Springer MD
Mr. Jason WadlerCommunity Volunteer
Board Demographics - Ethnicity
African American/Black 0
Asian American/Pacific Islander 0
Caucasian 11
Hispanic/Latino 0
Native American/American Indian 0
Board Demographics - Gender
Male 5
Female 6
Unspecified 0
Board Term Lengths 3
Board Term Limits 2
Board Meeting Attendance % 88%
Written Board Selection Criteria? Yes
Written Conflict of Interest Policy? Yes
Percentage Making Monetary Contributions 100%
Percentage Making In-Kind Contributions 100%
Constituency Includes Client Representation Yes
Number of Full Board Meetings Annually 4
Standing Committees
Scientific Advisory
CEO Comments
  • Without a doubt, the single biggest challenge for the VF is raising awareness about the disease itself.
  • VF members are encouraged to raise awareness of vasculitis year-round in their local communities. Awareness activities are directed at the general public and the medical community.
  • We hope to make 100% of the medical community aware of vasculitis and to provide them with the knowledge to diagnose and effectively treat the disease.
  • We also hope to make the general public aware of vasculitis so that they may better recognize the symptoms should they appear in their lives.
  • The VF is committed to providing educational resources that will provide a greater understanding of vasculitis in both the medical community and our patients. Greater understanding will ensure patients receive an earlier diagnosis and more effective treatments. Greater understanding of the disease process by patients will enable them to make educated and informed decisions about their treatments.
  • Through the VF website, newsletter, information packets, and one-on-one support, we educate patients about vasculitis. Our materials provide the most current information on vasculitis, its symptoms, medications, and side effects.
  • The VF connects vasculitis patients worldwide with experienced physicians for diagnosis and treatment and connects researchers with patients for critical research.
  • Educational meetings bring together our patients, families, and vasculitis experts. These meetings give patients the opportunity to meet others living with vasculitis – often making lifelong connections and friendships. It’s a layer of support that is priceless for those living with a rare disease.
  • Because of VF-funded vasculitis research, new and improved treatments and a greater understanding of vasculitis have increased the life expectancy for patients and also improved their quality of life.
  • Additional funding is critical to the Vasculitis Foundation because without it patients will not receive the information they need to successfully manage their disease. We are a partner to their medical team, providing them with support, information, connections, and sometimes just a listening ear.
  • With additional funding, we could reach more patients and more medical professionals. We could hold more educational meetings for patients, and for the doctors that treat them. We could make disease-specific information available in more languages. We could create programs that specifically target the pediatric and elderly populations.
  • With more funding, we could save lives.
Fiscal Year Start July 01, 2019
Fiscal Year End June 30, 2020
Projected Revenue $1,517,275
Projected Expenses $1,152,182
Endowment Value $242,458
IRS Letter of Exemption
Foundation Comments
  • FYE 6/30/2018, 2017, 2016: Financial data reported using IRS Form 990. 
  • Foundation/corporate revenue line item may include contributions from individuals.  
Detailed Financials
Revenue SourcesHelpThe financial analysis involves a comparison of the IRS Form 990 and the audit report (when available) and revenue sources may not sum to total based on reconciliation differences. Revenue from foundations and corporations may include individual contributions when not itemized separately.
Fiscal Year201820172016
Foundation and
Corporation Contributions
Government Contributions$0$0$0
Individual Contributions------
Investment Income, Net of Losses$27,123$23,021$17,641
Membership Dues$24,620$32,791$44,450
Special Events$146,700$143,237$74,874
Revenue In-Kind$795,975$1,023$3,857
Expense Allocation
Fiscal Year201820172016
Program Expense$793,982$1,070,852$847,205
Administration Expense$121,063$75,154$77,109
Fundraising Expense$70,831$15,340$26,740
Payments to Affiliates------
Total Revenue/Total Expenses1.101.190.92
Program Expense/Total Expenses81%92%89%
Fundraising Expense/Contributed Revenue------
Assets and Liabilities
Fiscal Year201820172016
Total Assets$1,500,959$1,391,746$1,150,881
Current Assets$145,915$113,300$165,872
Long-Term Liabilities$51,003$46,147$37,713
Current Liabilities$17,000$14,681$27,751
Total Net Assets$1,432,956$1,330,918$1,085,417
Short-Term Solvency
Fiscal Year201820172016
Current Ratio: Current Assets/Current Liabilities8.587.725.98
Long-Term Solvency
Fiscal Year201820172016
Long-Term Liabilities/Total Assets3%3%3%
Top Funding Sources
Fiscal Year201820172016
Top Funding Source & Dollar Amount --Virginia Mason Medical Center $300,000University of Pennsylvania $144,635
Second Highest Funding Source & Dollar Amount --University of Pennsylvania $265,037Genentech, Inc. $102,000
Third Highest Funding Source & Dollar Amount --Genentech $102,500Individual Donor $50,706
Capital Campaign
Currently in a Capital Campaign? No
Capital Campaign Anticipated in Next 5 Years No
Organization Comments
In 2006, the Vasculitis Foundation changed its name from the Wegener's Granulomatosis Association and expanded its mission to include supporting all vasculitic diseases.  This required an extensive review of all programs and a tremendous expansion of our services.  The VF relies on dues, donations, fundraising events and a small number of grants to support its efforts.  The VF is developing a comprehensive plan for pursuing grants; expanding our planned giving program and developing other fundraising efforts.  One of the main challenges for our organization is that many of our members are deeply committed to raising money for research but fail to see the importance of helping fund the Awareness and Support Programs.  Vasculitis has no known cause or cure and the treatment options are harsh with many side effects.  Our members want better treatments and they want a cure.  We need to educate our members about our programs and identify the members who will support them.
Other Documents
Vasculitis Foundation Research Report2016View
VF Annual Report2015View
VF Annual Report2014View
VF Annual Report2013View
Organization Name Vasculitis Foundation
Address PO Box 28660
Kansas City, MO 641888660
Primary Phone (816) 436-8211
CEO/Executive Director Ms. Joyce A Kullman
Board Chair Suzanne DePaolis
Board Chair Company Affiliation Community volunteer
Year of Incorporation 1986
Former Names
Wegener's Granulomatosis Association
Wegener's Granulomatosis Support Group, International